Is PD-L1 Just the Tip of the Iceberg?

Publication
Article
Precision Medicine in OncologyFebruary 2016
Volume 2
Issue 1

PD-1 and PD-L1 inhibition offers the possibility for precision immuno-oncology through the application of biomarkers that predict the immune systems response. This principle has been demonstrated by two of the most recent FDA approvals for patients with lung cancer.

OncLive Chairman,

Mike Hennessy

PD-1 and PD-L1 inhibition offers the possibility for precision immuno-oncology through the application of biomarkers that predict the immune systems response. This principle has been demonstrated by two of the most recent FDA approvals for patients with lung cancer.

In the first decision, the PD-1 inhibitor pembrolizumab (Keytruda) was granted an accelerated approval for pretreated patients with non—small cell lung cancer (NSCLC) who tests positive for PD-L1. This treatment was approved along with a companion diagnostic for selecting patients. In the pivotal trial that led to the drug's approval, those with PD-L1-positive disease were substantially more likely to respond compared with the negative group.

In a separate FDA decision, the FDA took a different course of action. In this decision, the PD-1 inhibitor nivolumab (Opdivo) was approved for pretreated patients with nonsquamous NSCLC. Although this decision was not specifically for those with PD-L1-positive lung cancer, it was approved along with a "complementary" PD-L1 diagnostic, to help guide treatment decisions.

As this field evolves, there will be many questions that still need to be answered. As Roy S. Herbst, MD, PhD, explained in the article, PD-L1 is only a moderately effective biomarker for immune checkpoint inhibitors and represents a few step in personalizing these therapies. Researchers are now digging deeper into predictors of response, including the BIM protein.

Biomarkers of response are not new to lung cancer; in fact, some could argue that NSCLC is furthest along in the race toward personalized medicine. Moving these advances beyond the established EGFR, ALK, and ROS1 biomarkers will represent the next challenge facing research.

Adjustments to clinical trial designs have already been made to shift the focus from histology to genomics. Umbrella, basket, and other novel clinical trial designs are enrolling participants based on their genetic alterations not type of cancer, with the hopes of uncovering truly personalized medicine.

As this research unfolds, Precision Medicine in Oncology will continue to cover the latest advances and provide updates on the current trends in utilizing these new therapies.

Thanks for reading!

Related Videos
Arya Amini, MD
Adrianna Masters, MD, PhD,
Chul Kim, MD, MPH
Andrew Ip, MD
In this final episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss a roadmap of artificial intelligence (AI) advances in the next 5 to 10 years.
In this eighth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, explain how artificial intelligence tools are being developed to match the right patient to the right drug on the right clinical trial.
In this seventh episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss how artificial intelligence tools may be utilized to improve wait time for treatment, to provide more time for provider-patient interactions, and more.
In this final episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, shed light on clinical outcomes following surgery of the primary tumor in patients with stage IV breast cancer.
In this sixth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss potential opportunities to leverage artificial intelligence tools in cancer screening, diagnosis, staging, and prognosis.
Christopher M. Gallagher, MD